Race Against Time: Combatting the Bundibugyo Ebola Outbreak

The Democratic Republic of Congo faces a critical health crisis due to an Ebola outbreak caused by the Bundibugyo strain. With no approved vaccines or treatments, global health authorities prioritize experimental candidates. The WHO leads efforts to assess promising vaccines and therapies to control and mitigate the epidemic's impact.

In an urgent bid to control the Ebola outbreak in the Democratic Republic of Congo, international health authorities are focusing on identifying possible medical interventions for the Bundibugyo strain of the virus. Unlike the more common Zaire strain, there are no approved vaccines or treatments for Bundibugyo.

The outbreak has resulted in 363 confirmed cases and 62 fatalities, with Bundibugyo ebolavirus proving fatal in up to 40% of cases. Although several experimental vaccines and therapies are under evaluation, their use depends on emergency or compassionate-use authorization, as they lack human testing data.

The World Health Organization is prioritizing several experimental options, including vaccine candidates like the single-dose rVSV Bundibugyo and ChAdOx1 Bundibugyo, and antibody-based therapies such as Mapp Biopharmaceutical's MBP134 and Regeneron's maftivimab. Antiviral drugs, including Gilead's obeldesivir and remdesivir, are also under consideration to curb the outbreak.